DB18589ExperimentalProtein Based Therapies
2G7 is an anti-TGF-beta monoclonal antibody developed by Genentech.
- Mechanism
- Curator reviewed
Pharmacologically active on Transforming growth factor beta-1 proprotein, Transforming growth factor beta-2 proprotein, and Transforming growth factor beta-3 proprotein
- Also known as
- Anti-TGF-beta 2G7 · Anti-TGF-beta antibody 2G7 · Anti-TGF-beta monoclonal antibody 2G7 · Anti-transforming growth factor-beta monoclonal antibody 2G7 · Recombinant humanized anti-transforming growth factor (TGF) beta 3 antibody
Resolves to
What you can answer from here — as of July 09, 2026
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with 2G7, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account